Adenovirus Vectors for High-Security and Disaster Relief Settings

This inventive concept adapts adenovirus vectors for specialized applications in high-security facilities and disaster relief settings, ensuring the safe and effective delivery of vaccines in extreme environments.

Traditional adenovirus vectors, as described in the original patent, may not be suitable for use in high-security facilities or disaster relief settings due to concerns about bioterrorism threats, extreme weather conditions, and the need for secure storage and delivery. This inventive concept addresses these limitations by designing adenovirus vectors specifically for these niche applications.

The inventive concept involves the development of adenovirus vectors comprising a capsid with one or more capsid proteins from chimpanzee adenovirus AdY25, which encapsidate a nucleic acid molecule comprising an exogenous nucleotide sequence of interest operably linked to expression control sequences. These vectors are specifically designed for use in high-security facilities to prevent bioterrorism threats, in post-disaster relief settings to address the needs of affected populations, or in extreme weather conditions such as cold climates. The vectors may be formulated to remain stable under these conditions, and may be delivered using secure storage and delivery devices.

The new claims introduce novel and non-obvious features, including the specific design of adenovirus vectors for high-security facilities and disaster relief settings, the formulation of vectors for stability under extreme weather conditions, and the use of secure storage and delivery devices. These features distinguish the inventive concept from the original patent and provide a significant advance in the field.

Alternative embodiments of the inventive concept may include adenovirus vectors designed for use in other specialized settings, such as extreme heat or high-altitude environments. Variations may include the use of different adenovirus serotypes or the incorporation of additional features, such as tracking devices or sensors, to enhance the security and effectiveness of vaccine delivery.

The inventive concept has significant commercial potential in the vaccine industry, particularly in the areas of biodefense and disaster relief. The target market includes government agencies, non-profit organizations, and private companies involved in vaccine development and delivery for high-security and disaster relief settings.